Biofrontera
Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. In February 2012 Biofrontera launched the prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through various local representatives. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. US FDA approval of Ameluz® and activating PDT-lamp BF-RhodoLED® for the treatment of actinic keratoses was granted in May 2016. As a cosmeceutical product Biofrontera markets Belixos® creme for the regenerative care of reddened and inflamed skin. It is Biofrontera’s intention to develop a line of cosmeceutical products for damaged skin under the Belixos brand. The Biofrontera Group consists of the parent company Biofrontera AG and five wholly owned direct subsidiaries - Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, Biofrontera Neuroscience GmbH and Biofrontera Inc. Biofrontera Inc. has its registered office in Wakefield, MA, USA. All the other companies are based at Hemmelrather Weg 201 in 51377 Leverkusen, Germany. The listed public limited company (AG in German) has a holding function in the group of companies and ensures the necessary financing for the Group. Biofrontera Bioscience GmbH undertakes the research and development tasks for the Group and is the holder of patents and the approval for Ameluz®. Based on a licence agreement with Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, which is also the holder of the approval for BF-RhodoLED®, is responsible for the manufacturing and also the further licensing and marketing of the Biofrontera Group’s approved products. Biofrontera Development GmbH and Biofrontera Neuroscience GmbH were established as additional wholly owned subsidiaries of Biofrontera AG in December 2012. The purpose of both companies is to pursue the further development of pipeline products that are not part of Biofrontera's core business and therefore cannot be sufficiently financed within the framework of normal business development. The product BF-derm1, which is intended for the treatment of severe chronic urticaria, is the responsibility of Biofrontera Development GmbH, while the product BF-1, which is intended for the prophylactic treatment of migraines, is the responsibility of Biofrontera Neuroscience GmbH. By outsourcing the development projects, a structure has been created through which the financing of the further development of these two products can be separated from the normal Group financing. Biofrontera Inc. was established in March 2015 and will be used to conduct business in the USA.
Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin. In February 2012 Biofrontera launched the prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through various local representatives. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012. US FDA approval of Ameluz® and activating PDT-lamp BF-RhodoLED® for the treatment of actinic keratoses was granted in May 2016. As a cosmeceutical product Biofrontera markets Belixos® creme for the regenerative care of reddened and inflamed skin. It is Biofrontera’s intention to develop a line of cosmeceutical products for damaged skin under the Belixos brand. The Biofrontera Group consists of the parent company Biofrontera AG and five wholly owned direct subsidiaries - Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH, Biofrontera Neuroscience GmbH and Biofrontera Inc. Biofrontera Inc. has its registered office in Wakefield, MA, USA. All the other companies are based at Hemmelrather Weg 201 in 51377 Leverkusen, Germany. The listed public limited company (AG in German) has a holding function in the group of companies and ensures the necessary financing for the Group. Biofrontera Bioscience GmbH undertakes the research and development tasks for the Group and is the holder of patents and the approval for Ameluz®. Based on a licence agreement with Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, which is also the holder of the approval for BF-RhodoLED®, is responsible for the manufacturing and also the further licensing and marketing of the Biofrontera Group’s approved products. Biofrontera Development GmbH and Biofrontera Neuroscience GmbH were established as additional wholly owned subsidiaries of Biofrontera AG in December 2012. The purpose of both companies is to pursue the further development of pipeline products that are not part of Biofrontera's core business and therefore cannot be sufficiently financed within the framework of normal business development. The product BF-derm1, which is intended for the treatment of severe chronic urticaria, is the responsibility of Biofrontera Development GmbH, while the product BF-1, which is intended for the prophylactic treatment of migraines, is the responsibility of Biofrontera Neuroscience GmbH. By outsourcing the development projects, a structure has been created through which the financing of the further development of these two products can be separated from the normal Group financing. Biofrontera Inc. was established in March 2015 and will be used to conduct business in the USA.
Biofrontera has raised $16.0M across 1 round. Its most recent round was a Series Unknown of $16.0M in Feb 2024. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Biofrontera is featured in
Similar companies
Tubulis creates specialized chemotherapy drugs that target cancer and chronic illnesses by combining unique technology with disease-specific biological knowledge. This allows medical professionals to treat cancer patients with fewer side effects than traditional chemotherapy.
Artcline is a biotech company that creates diagnostic and therapeutic techniques for critical care medicine.
Detechgene is a biotech firm that creates a cartridge system for conducting diagnostics.
Mainz Biomed strives to be a prominent supplier of accessible diagnostic solutions for individuals worldwide. Our focus is on creating inventive products that efficiently detect the early stages of various life-threatening illnesses, such as colorectal and pancreatic cancers. For additional information about our company and our commitment to using science to preserve lives, please visit our website at www.mainzbiomed.com.
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in the mental health space. ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany.
Pheiron offers a platform that is scalable, secure, and interoperable for managing health data using advanced analytics. The company's main focus is on increasing the chances of success in drug development by utilizing causal insights on targets and populations. Pheiron employs artificial intelligence to analyze various types of data related to diseases, with the goal of improving understanding and informing decisions in the drug development process. Additionally, the platform enables large-scale analysis of exome sequences to identify factors specific to sex and age in health management.
Ethris is paving a new path from genes to therapeutic proteins using our proprietary messenger RNA technology. Developed in-house, our integrated platform enables the discovery, design and development of transcript therapies that restore missing functions in patients’ cells and tissues. We will advance transcript therapies to transform the treatment of disease independently and with our partners.
Vivoryon Therapeutics, a biopharmaceutical company headquartered in Germany, is dedicated to conducting research and development as well as preclinical and clinical trials. Their primary focus is on creating therapeutic treatments for Alzheimer's disease and cancer, with pipeline products such as PQ912, PQ1565, and other PQ-family medications.
SynBiotic is harnessing the healing capabilities of cannabinoids to address a range of illnesses, bringing together various resources in one place for easier access. They provide relief for conditions such as chronic pain, stress, and sleep disorders, which can greatly impact both physical and mental health.
HepaRegeniX is creating medications to treat acute and chronic liver diseases by restoring the regenerative ability of hepatocytes. This therapeutic method is based on research conducted by Professor Lars Zender's team at the University Hospital Tübingen, which identified MKK4 as a crucial factor in liver regeneration. The team found that suppressing the MKK4 gene through small RNA molecules could enhance the regenerative capaUK hepatocytes in diseased livers. Founded in 2015, HepaRegeniX is working on developing MKK4 inhibitors as a potential treatment for liver disorders, including nonalcoholic steatohepatitis.
Akribion Genomics utilizes CRISPR nuclease technology to create gene-editing tools and treatments for cancer.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.